Xilio Therapeutics (NASDAQ:XLO) Releases Earnings Results, Beats Expectations By $0.64 EPS

Xilio Therapeutics (NASDAQ:XLO) announced its earnings results on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.64, FiscalAI reports. Xilio Therapeutics had a negative return on equity of 71.99% and a negative net margin of 34.06%. The firm had revenue of $9.98 million during the quarter, compared to analyst estimates of $4.92 million.

Xilio Therapeutics Trading Up 0.4%

Shares of XLO stock traded up $0.04 during trading hours on Tuesday, reaching $9.04. The company’s stock had a trading volume of 1,686 shares, compared to its average volume of 32,398. Xilio Therapeutics has a one year low of $6.47 and a one year high of $11.30. The stock has a market capitalization of $59.48 million, a P/E ratio of -5.51 and a beta of -0.13. The firm’s fifty day simple moving average is $8.75 and its 200 day simple moving average is $8.50.

Analysts Set New Price Targets

Several equities research analysts have issued reports on XLO shares. Raymond James Financial started coverage on Xilio Therapeutics in a research report on Wednesday, October 21st. They set an “outperform” rating and a $16.00 target price on the stock. Weiss Ratings upgraded Xilio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Finally, Zacks Research upgraded shares of Xilio Therapeutics to a “hold” rating in a research report on Thursday, October 22nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Xilio Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $16.00.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for cancer. The company’s technology is designed to keep powerful immune-modulating medicines inactive in healthy tissue and activate them preferentially within the tumor microenvironment, with the goal of improving antitumor activity while reducing systemic side effects.

Xilio’s research and development programs have included engineered cytokines and immune checkpoint therapies, including tumor-activated versions of interleukin-2, interleukin-12 and CTLA-4-directed treatments.